Senti Biosciences Inc
SNTI1.940USD
+0.130+7.18%
收盘 11/05, 16:00（美东）报价延迟15分钟
50.75M总市值
亏损市盈率 TTM
关于 Senti Biosciences Inc 公司
Senti Biosciences, Inc. 是一家临床阶段的生物技术公司。该公司正在利用其基因回路平台技术为患有无法治愈的疾病的患者开发细胞和基因疗法。该公司专注于针对肿瘤适应症的现成 CAR-NK 细胞疗法项目。其主要候选产品 SENTI-202 是一种潜在的逻辑门控现成 CAR-NK 细胞疗法，旨在选择性靶向和消除表达 CD33 和/或 FLT3 的血液系统恶性肿瘤，包括急性髓细胞白血病，同时保留健康的骨髓细胞。其第二个临床开发项目是 SENTI-301A，这是一种多臂现成的健康供体衍生 CAR-NK 细胞疗法。SENTI-202 旨在使用逻辑门控基因回路整合三种嵌合蛋白并通过单个逆转录病毒递送。 SENTI-301A 是一种多臂现成的健康供体衍生的 CAR-NK 细胞疗法，旨在治疗晚期 GPC3 阳性肿瘤。
Senti Biosciences Inc简介
公司代码SNTI
公司名称Senti Biosciences Inc
上市日期May 26, 2021
CEODr. Timothy (Tim) Lu, M.D., Ph.D.
员工数量34
证券类型Ordinary Share
年结日May 26
公司地址2 Corporate Drive, First Floor
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94080
电话16502392030
网址https://www.sentibio.com/
公司代码SNTI
上市日期May 26, 2021
CEODr. Timothy (Tim) Lu, M.D., Ph.D.
Senti Biosciences Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Mr. Bryan Baum
Mr. Bryan Baum
Director
Director
--
--
Ms. Frances D. Schulz
Ms. Frances D. Schulz
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Donald Tang
Mr. Donald Tang
Director
Director
--
--
Mr. Jay Cross
Mr. Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. Feng Hsiung
Mr. Feng Hsiung
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Mr. Bryan Baum
Mr. Bryan Baum
Director
Director
--
--
Ms. Frances D. Schulz
Ms. Frances D. Schulz
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月31日 周五
更新时间: 10月31日 周五
持股股东
股东类型
持股股东
持股股东
占比
Celadon Partners SPV 24
37.37%
New Enterprise Associates (NEA)
14.43%
Bayer HealthCare LLC
10.74%
PharmaEssentia Corp.
8.07%
Armistice Capital LLC
3.41%
其他
25.97%
持股股东
持股股东
占比
Celadon Partners SPV 24
37.37%
New Enterprise Associates (NEA)
14.43%
Bayer HealthCare LLC
10.74%
PharmaEssentia Corp.
8.07%
Armistice Capital LLC
3.41%
其他
25.97%
股东类型
持股股东
占比
Corporation
56.18%
Venture Capital
14.43%
Hedge Fund
6.81%
Investment Advisor
3.90%
Individual Investor
0.85%
Investment Advisor/Hedge Fund
0.63%
其他
17.19%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
48
6.74M
25.78%
-1.11M
2025Q2
59
22.40M
85.87%
+17.02M
2025Q1
61
32.06M
123.04%
+28.81M
2024Q4
55
2.74M
57.01%
+442.53K
2024Q3
56
2.03M
44.31%
-591.63K
2024Q2
59
2.00M
43.68%
-736.88K
2024Q1
91
2.11M
47.03%
-1.57M
2023Q4
97
2.11M
47.62%
-1.61M
2023Q3
101
2.43M
55.03%
-1.49M
2023Q2
105
2.45M
55.45%
-1.56M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Celadon Partners SPV 24
9.78M
37.37%
--
--
Aug 29, 2025
New Enterprise Associates (NEA)
3.78M
14.43%
--
--
Jun 30, 2025
Bayer HealthCare LLC
2.81M
10.74%
+2.22M
+377.99%
Mar 10, 2025
PharmaEssentia Corp.
2.11M
8.07%
--
--
Apr 28, 2025
Armistice Capital LLC
892.21K
3.41%
-547.61K
-38.03%
Jun 30, 2025
Nantahala Capital Management, LLC
888.00K
3.39%
--
--
Jun 30, 2025
Heights Capital Management, Inc.
381.38K
1.46%
-368.62K
-49.15%
Jun 30, 2025
The Vanguard Group, Inc.
360.91K
1.38%
+206.78K
+134.15%
Jun 30, 2025
8VC GP I, LLC
253.75K
0.97%
--
--
Jun 30, 2025
Lu (Timothy K M.D., Ph.D.)
161.63K
0.62%
--
--
Apr 28, 2025
查看更多
持股ETF
更新时间: 1 小时前
更新时间: 1 小时前
机构名称
占比
iShares Micro-Cap ETF
0%
ARK Genomic Revolution ETF
0%
iShares Micro-Cap ETF
占比0%
ARK Genomic Revolution ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
公告日期
类型
比率
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
